At Adaptive Phage Therapeutics, our mission is to save lives or restore patient health by developing safe, effective, and durable antimicrobial therapeutics. We harness the diversity and specificity of curated bacteriophages to advance sustainable and accessible treatments that adapt to maintain effectiveness against the emergence of resistant bacterial pathogens.
Clinical studies at Adaptive Phage Therapeutics
Currently, APT has the following clinical studies in progress or planning:
DANCE: A clinical trial in DFO
This study is currently recruiting patients at sites around the United States. The goal is to learn whether phage are a safe and effective form of treatment for foot ulcers associated with foot bone infections in patients with diabetes.
ACTIVE: A clinical trial for chronic PJI
This study is planning to start recruiting in early 2023 at sites around the United States. The goal is to learn whether phage are a safe and effective treatment for infections after joint replacements when given with antibiotics and debridement.
Contact us for information on participating
If you would like to find out more about our clinical studies, or see if you might qualify to participate, contact us at email@example.com or 844-799-2744.
What is a clinical study?
Clinical studies are research studies which recruit people to evaluate new potential medical treatments, such as medications, medical devices, disease screenings, and mental health interventions. This is the main way that researchers, as well as your doctors and other medical professionals, find out if new medical treatments are safe and effective in people.
Some clinical trials look at whether a new potential treatment works better and/or has fewer side effects than current treatments. Other clinical trials may look at ways to find diseases earlier, prevent future health problems, or lessen symptoms of life-long diseases.
The US Food and Drug Administration, also known as the FDA, reviews potential medical treatments before clinical trials begin in people. The FDA reviews all information related to the potential medical treatment such as results from studies in animals and studies in laboratories. If the new potential medical treatment can possibly help patients in the future, and results from laboratory studies support that it is safe and possibly helpful, the FDA will allow the new medical treatment to be used in clinical trials with people.
If you meet the criteria to be part of this trial, and you give your consent to join, you will receive the current standard‑of‑care treatment for your condition from your study physician. Additionally, as part of your joining the trial, you will randomly be put into 1 of 2 groups: 1) a group that receives only the standard‑of‑care treatment plus a placebo, or 2) a group that receives the standard of care plus phage treatment.
Placebo is a harmless substance identical in appearance to phage treatment, but with no phages in it. If you are randomly placed into the placebo group you will still receive the standard‑of‑care treatment for your condition from your physician, but you will only receive placebo as part of your participation in this trial.
If you are placed in the treatment group, you will receive the standard‑of‑care treatment as well as phage treatment. Your physician will take bacteria from your infection and the bacteria will be matched to a specific type of phage that will only attack and infect the bacteria from your infection. The phage treatment will not harm other cells in your body, including not harming the “good” bacteria that are meant to be in your body.